Protagonist Therapeutics, Inc. (PTGX)
NASDAQ: PTGX · Real-Time Price · USD
38.10
+1.28 (3.48%)
Jan 21, 2025, 4:00 PM EST - Market closed
Protagonist Therapeutics Stock Forecast
Stock Price Forecast
The 8 analysts with 12-month price forecasts for PTGX stock have an average target of 54.63, with a low estimate of 43 and a high estimate of 65. The average target predicts an increase of 43.39% from the current stock price of 38.10.
Analyst Consensus: Strong Buy
* Price targets were last updated on Dec 10, 2024.
Analyst Ratings
The average analyst rating for PTGX stock from 8 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 | Jan '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 4 | 4 | 4 | 4 | 4 |
| Buy | 3 | 3 | 3 | 3 | 4 | 4 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 7 | 7 | 7 | 8 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $50 | Strong Buy | Reiterates | $50 | +31.23% | Dec 10, 2024 |
| BMO Capital | BMO Capital | Buy Initiates $62 | Buy | Initiates | $62 | +62.73% | Dec 6, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $50 | Strong Buy | Reiterates | $50 | +31.23% | Nov 22, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $50 | Strong Buy | Reiterates | $50 | +31.23% | Nov 19, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $50 | Strong Buy | Reiterates | $50 | +31.23% | Nov 11, 2024 |
Financial Forecast
Revenue This Year
324.65M
from 60.00M
Increased by 441.08%
Revenue Next Year
102.91M
from 324.65M
Decreased by -68.30%
EPS This Year
2.53
from -1.39
EPS Next Year
-1.55
from 2.53
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 450.2M | 191.6M | 424.2M | |||
| Avg | 324.7M | 102.9M | 130.4M | |||
| Low | 258.5M | n/a | 19.6M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 650.4% | -41.0% | 312.2% | |||
| Avg | 441.1% | -68.3% | 26.7% | |||
| Low | 330.9% | - | -81.0% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 4.35 | -0.17 | -1.16 | |||
| Avg | 2.53 | -1.55 | -1.99 | |||
| Low | 1.55 | -2.37 | -3.63 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.